Ameriprise’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-17,396
| Closed | -$3M | – | 4108 |
|
|
2021
Q3 | $3M | Sell |
17,396
-536,878
| -97% | -$70.2M | ﹤0.01% | 2698 |
|
|
2021
Q2 | $69.6M | Buy |
554,274
+566
| +0.1% | +$71.4K | 0.02% | 652 |
|
|
2021
Q1 | $75.1M | Sell |
553,708
-2,174
| -0.4% | -$281K | 0.03% | 605 |
|
|
2020
Q4 | $71.1M | Sell |
555,882
-271,032
| -33% | -$31.8M | 0.03% | 588 |
|
|
2020
Q3 | $93.1M | Buy |
826,914
+435,539
| +111% | +$43.4M | 0.04% | 447 |
|
|
2020
Q2 | $37.3M | Buy |
391,375
+279,156
| +249% | +$26.9M | 0.02% | 733 |
|
|
2020
Q1 | $10.1M | Buy |
+112,219
| New | +$8.72M | 0.01% | 1380 |
|
|
2019
Q1 | – | Sell |
-23,004
| Closed | -$1M | – | 3806 |
|
|
2018
Q4 | $1M | Sell |
23,004
-10
| -0% | -$500 | ﹤0.01% | 2937 |
|
|
2018
Q3 | $1.32M | Buy |
+23,014
| New | +$1.13M | ﹤0.01% | 2969 |
|
|
2017
Q4 | – | Sell |
-33,430
| Closed | -$1.25M | – | 3768 |
|
|
2017
Q3 | $1.25M | Buy |
+33,430
| New | +$1.16M | ﹤0.01% | 2867 |
|
|
2015
Q1 | – | Sell |
-23,317
| Closed | -$908K | – | 3954 |
|
|
2014
Q4 | $908K | Buy |
+23,317
| New | +$813K | ﹤0.01% | 2917 |
|
Ameriprise's XLRN Position: Q4 2021 in Review
Ameriprise sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 17,396 shares — an estimated $3M sold.
Ameriprise first reported a position in XLRN in Q4 2014 and held it in 11 quarters. The position peaked at $93.1M in Q3 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Ameriprise reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Ameriprise sold 17,396 Acceleron Pharma shares in Q4 2021, an estimated $3M.
- Ameriprise first reported a position in Acceleron Pharma in Q4 2014 and held it in 11 quarters.
- Ameriprise's Acceleron Pharma position peaked at $93.1M in Q3 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Ameriprise's 13F filing for Q4 2021, filed 14 Feb 2022.